within Pharmacolibrary.Drugs.ATC.B;

model B02BB01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 6e-05,
    adminDuration  = 600,
    adminMass      = 70 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 5e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B02BB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fibrinogen, human, is a plasma-derived coagulation factor used for the treatment of congenital or acquired fibrinogen deficiency, such as in cases of bleeding disorders, afibrinogenemia, or hypofibrinogenemia. It is administered to restore hemostasis and is approved for clinical use, most notably in the setting of active bleeding or perioperative management in patients with low fibrinogen levels.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported for adult patients (median age: 34 years, range: 8 to 81 years) with congenital fibrinogen deficiency receiving intravenous administration of human fibrinogen concentrate.</p><h4>References</h4><ol><li><p>Piechowski-Jozwiak, B, et al., &amp; Bogousslavsky, J (2022). Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase. <i>European journal of drug metabolism and pharmacokinetics</i> 47(2) 165–176. DOI:<a href=\"https://doi.org/10.1007/s13318-021-00743-8\">10.1007/s13318-021-00743-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34893967/\">https://pubmed.ncbi.nlm.nih.gov/34893967</a></p></li><li><p>Ross, C, et al., &amp; Peyvandi, F (2018). Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. <i>Journal of thrombosis and haemostasis : JTH</i> 16(2) 253–261. DOI:<a href=\"https://doi.org/10.1111/jth.13923\">10.1111/jth.13923</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29220876/\">https://pubmed.ncbi.nlm.nih.gov/29220876</a></p></li><li><p>Raggio, MJ, &amp; Morris, PE (2004). Drotrecogin alfa. <i>Drugs of today (Barcelona, Spain : 1998)</i> 40(6) 517–538. DOI:<a href=\"https://doi.org/10.1358/dot.2004.40.6.850484\">10.1358/dot.2004.40.6.850484</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15349131/\">https://pubmed.ncbi.nlm.nih.gov/15349131</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B02BB01;
